NaxSwab OTC naloxone nasal swab demonstrates faster absorption and higher early exposures against other naloxone products in clinical study
BETHESDA, Md., Dec. 1, 2022. Pocket Naloxone Corp., a startup pharmaceutical company with the vision of enhancing naloxone delivery, today announced positive results from its human pharmacokinetic (PK) study of its novel naloxone nasal swab NaxSwab.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 1, 2022 Category: Pharmaceuticals Source Type: clinical trials

ASKB589 in Combination With CAPOX and Mentsimab in Patients With Locally Advanced or Metastatic Solid Tumors.
Condition:   Advanced Solid Tumors Intervention:   Biological: ASKB589 Injection Sponsors:   AskGene Pharma, Inc.;   Jiangsu Aosaikang Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2022 Category: Research Source Type: clinical trials

Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm® (aducanumab-avwa)-treated patients at 6 months Donanemab reduced brain amyloid plaque levels vs. baseline by... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 1, 2022 Category: Pharmaceuticals Source Type: clinical trials

FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region
November 30, 2022 -- The U.S. Food and Drug Administration today announced bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1., according to data... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 1, 2022 Category: Pharmaceuticals Source Type: clinical trials

Acoziborole: Investigational Single-Dose Oral Treatment Raises Hope for Elimination of Sleeping Sickness in Africa
Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa Positive Phase II/III study results support acoziborole’s potential in treatment for deadly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 30, 2022 Category: Pharmaceuticals Source Type: clinical trials

Green-Tinted Eyeglasses May Reduce The Need For Opioids To Manage Severe Pain
WILMINGTON, N.C., Nov. 30, 2022,  A recent study showed that wearing special green-tinted eyeglasses reduces pain in patients with fibromyalgia and others who experience chronic pain. This may help decrease the need for opioids to manage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 30, 2022 Category: Pharmaceuticals Source Type: clinical trials

Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease published in the NEJM
STOCKHOLM, Nov. 30, 2022. BioArctic AB ' s partner Eisai announced today that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 30, 2022 Category: Pharmaceuticals Source Type: clinical trials

WHO Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
GAITHERSBURG, Md., Nov. 29, 2022. Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 29, 2022 Category: Pharmaceuticals Source Type: clinical trials

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer ’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference
TOKYO and CAMBRIDGE, November 29, 2022 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, " Eisai " ) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, " Biogen " ) announced today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 29, 2022 Category: Pharmaceuticals Source Type: clinical trials

US Partial Clinical Hold on Diamyd Phase III Trial Lifted by the FDA
STOCKHOLM, Nov. 28, 2022. Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, evaluating the safety and efficacy of the precision... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2022 Category: Pharmaceuticals Source Type: clinical trials

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2022 Category: Pharmaceuticals Source Type: clinical trials

Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 27,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 27, 2022 Category: Pharmaceuticals Source Type: clinical trials

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar
Condition:   Vocal Fold Scar Interventions:   Drug: KP-100LI;   Drug: Placebo Sponsor:   Kringle Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 25, 2022 Category: Research Source Type: clinical trials